Physician profile
Julie Patel
NPI 1417244971
$2,877.25
in general payments reported to CMS, 2019-2025
24 companies · $834 in 2025
The $834 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.30 · 2020: $39.22 · 2021: $66.35 · 2022: $79.29 · 2023: $777 · 2024: $1,022 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.10 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $550.56 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $351.18 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $285.20 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $213.55 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $179.01 | 2021-2025 | |
| Lilly USA, LLC | $145.97 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $136.76 | 2023-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $136.17 | 2023-2024 | |
| Pfizer INC. | $134.96 | 2020-2025 | |
| Exact Sciences Corporation | $121.47 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $105.11 | 2023-2024 | Heplisav-B |
| Sumitomo Pharma America, INC. | $97.15 | 2024-2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $80.97 | 2023-2024 | Austedo Xr, Austedo |
| Abbott Laboratories | $77.72 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $42.44 | 2024 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.00 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $36.33 | 2024-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $25.58 | 2024 | |
| Hologic Sales and Service, LLC | $24.45 | 2024 | Aptima |
| Idorsia Pharmaceuticals US INC | $21.10 | 2023 | Quviviq |
| Ultragenyx Pharmaceutical INC. | $19.81 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.57 | 2023 | |
| Ibsa Pharma INC. | $17.71 | 2024 | Tirosint, Licart |
| Revance Therapeutics, INC. | $14.48 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.